Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities.

Slides:

Advertisements

Similar presentations

What is the Optimal Approach to CLL, BR vs. FCR/FR?

Advertisements

New Data for Old Drugs in CLL Kanti R. Rai MD Joel Finkelstein Cancer Foundation Professor of Medicine Hofstra North Shore-LIJ School of Medicine Hempstead,

Roberts AW et al. Proc ASH 2014;Abstract 325.

Integrazione del profilo clinico-biologico con le nuove opzioni terapeutiche Francesca R Mauro Dipartimento di Biotecnologie Cellulari ed Ematologia Università.

Agne Paner, MD Assistant professor of Medicine RUSH University Medical Center.

The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and is Tolerable in Treatment- Naïve.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

Kanti R. Rai, MD NSLIJ-Hofstra School of Medicine Long Island Jewish Medical Center New Hyde Park, NY Hematology Highlights 2013 Expert Reviews of the.

Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine.

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Idelalisib (GS- 1101) in Combination with Rituximab and/or Bendamustine.

Second Interim Analysis of a Phase 3 Study of Idelalisib Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient.

Ibrutinib in Combination with Rituximab (iR) Is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High- Risk Chronic Lymphocytic.

Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in Previously Untreated and.

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC

Which is the optimal approach: BR or FCR/FR?

Chen R et al. Proc ASH 2015;Abstract 518.

Idelalisib plus Bendamustine and Rituximab (BR) Is Superior to BR Alone in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of a.

Goede V et al. Proc ASH 2014;Abstract 3327.

Novel Regimens and Considerations in Radionuclide Therapy for mCRPC

WHAT IS THE BEST Front-Line REGIMEN for Patients With CLL

Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.

Current and Future Goals in the Treatment of Relapsed CLL

Goals of Therapy in Relapsed CLL

Advances in Lymphoma.

Updates in Follicular Lymphoma

Novel and Emerging Approaches to Treating CLL

The Nurse View.

Activity Goals. Activity Goals Case Presentation.

Jonathan W. Friedberg M.D., M.M.Sc.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Management Challenges in CLL

Updates in Lymphoma From Recent Congresses

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Managing Adverse Events With New Oral Therapies in CLL

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Optimizing Outcomes and Managing Adverse Events in CLL

Personalized Therapy in Relapsed or Refractory CLL

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Interprofessional Approaches: Managing AEs of Novel Therapies for NHL/CLL.

Patient-Centered Management in Pancreatic Cancer

What is the best frontline regimen for CLL patients

PAH and Prostacyclin Pathways in Focus

Non-Chemotherapy Combinations in CLL

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Evaluating BTK Inhibitors in CLL

Crossover for pts meeting ELN 2013 failure criteria

Assessing New Paradigms in CLL: MRD Negativity

FDA-Approved PI3K Inhibitors for CLL and FL

LBA-4 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy.

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Dr Parag Jasani Consultant Haematologist UCLH

Managing CLL With BTK Inhibitors

First-Line FCR: Effect of del(17p) on PFS and OS

Improving Outcomes in Patients With SSc-ILD

Oral Treatment Strategies in CLL

Disease Burden of VTE Phases of VTE Treatment.

Tailoring Therapy in the Newly Diagnosed Patient With CLL

How to Select Therapy in Relapsed/Refractory CLL

An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Changing Paradigms in Relapsed/Refractory Indolent NHL

Treatment Initiation and Selection in Newly Diagnosed CLL

Optimizing therapy for nodal marginal zone lymphoma

Utilizing MRD Assessment in Community Practice

Presentation transcript:

Individualizing Therapy for Patients With CLL in the Community Practice Setting: Focus on Age and Comorbidities

Activity Goals

Extended Follow-up CLL8 (GCLLSG)

CLL5 Protocol: Overall Survival

PFS in Patients > 70 y: Across Treatment Regimens

Fludarabine (F) vs Chlorambucil (Ch) by Age Group < or > 65 y

PFS: Ch vs Bendamustine (B) in Untreated CLL

Ch + Rituximab (R) in Symptomatic, Previously Untreated CLL

Ch + R in Symptomatic, Previously Untreated CLL

Targeting of BCR Signaling With Ibrutinib

Phase 2 (PCYC-1102-CA) in CLL/SLL

Phase 2: Best Response by Risk Features

Phase 2: PFS

Phase 2: PFS by Prognostic Factors

Ibrutinib and Rituximab (IR) in High-Risk CLL

Transient Lymphocytosis on IR in High-Risk CLL

Lymph Node Responses Assessed by CT (31 Evaluable Patients)

Idelalisib + Rituximab in Frontline CLL

Nodal Response: Idelalisib + Rituximab

Response: Idelalisib + Rituximab

PFS: Idelalisib + Rituximab

Conclusions

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)